Elobixibat plus sodium picosulfate with magnesium citrate for bowel preparation

Efficacy and tolerability of elobixibat plus sodium picosulfate with magnesium citrate versus split dose 2-L polyethylene glycol with ascorbic acid for bowel preparation before outpatient colonoscopy:A multicenter, randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041210067

Enrollment

540

Registered

2021-09-09

Start date

2021-09-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bowel preparation before colonoscopy

Interventions

Randomized controlled trial for new method bowel preparation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Out-patients who are planned scheduled colonoscopy (2) Patients aged 40 to 69 years old at the time of consent (3) Patients who received sufficient explanation about the trial and agreed with signatures

Exclusion criteria

Exclusion criteria: (1) Patients who had been registered in this trial (2) Patients who have allergic reaction of drugs used in this trial (3) PS(ECOG)>=2 (4) Patients who have symptoms or signs of bowel obstruction or colorectal strictures (5) Patients who had symptoms of constipations

Design outcomes

Primary

Measure	Time frame
Bowel preparation scale (BBPS>=6, Per each segment>=2)	—

Secondary

Measure	Time frame
(1) Patients' tolerability (Questionnaire) (2) Incidence of adverse effects (3) Polyp/adenoma detection rate,The number of polyp/adenoma (4) Bowel preparation scale(BBPS>=8) (5) Bowel preparation scale(Aronchick scale<=1) (6) Time of bowel preparation (7) The volume of the bowel cleansing solution	—

Contacts

Public ContactKinichi Hotta

Shizuoka Cancer Center

k.hotta@scchr.jp+81-55-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026